Medical Device and Diagnostics Public Relations

	Recent Medical Device and Diagnostics Public Relations Coverage
	Scientific American TruFocals was featured in article on how NASA is evaluating the adjustable focus vision technology for use by astronauts in space. Link to Article
	The Mercury This feature story on the INBONE Total Ankle Replacement from Wright Medical tells the tale of a suburban Philadelphia woman whose artificial ankle allowed her to reclaim the active lifestyle that had been hampered by the onset of degenerative arthritis in her ankle. Link to Article

From its inception, Schwartz Communications has designed, developed and executed high-impact public relations campaigns on behalf of some of the nation's most innovative and exciting medical device and diagnostic companies. We develop comprehensive communications programs that help our clients meet the demands of today’s market, from elevating brand awareness and driving physician demand, to stimulating consumer awareness and clinical trial enrollment, to publicizing key regulatory milestones and peer-reviewed research. We actively partner with our clients to develop crisis communications plans, cement relationships with influential advocacy groups and obtain product reimbursement from insurers.

Schwartz has been involved with some of the most visible medical public relations campaigns of the past decade. The agency’s first client was Heart Technology, which we guided through an initial product launch, IPO, FDA-mandated product recall and, finally, a $500 million acquisition by Boston Scientific. More recently, our award-winning healthcare practice has developed the strategy and executed the tactics for PR campaigns that have:

• Dramatically escalated Public Access Defibrillation into a major public health issue with an eight-year campaign that began with a small start-up (Heartstream) and continues now for Philips Medical Systems.
• Catapulted CYTYC, the developer of the ThinPrep Pap test and our client since 1998, from 15 percent to more than 70 percent marketshare in the U.S., driven in part by the patient demand created by our DTC PR efforts.
• Drove massive national and international visibility for client Syncardia, whose Total Artificial Heart (TAH) is the first artificial heart to be approved by the FDA.
• Assisted our client Gynecare in introducing the first-ever outpatient, non-invasive treatment for menorhaggia (excessive menstrual bleeding). The company was subsequently acquired by Ethicon, Inc.
• Introduced the first and only device to treat epilepsy for our client Cyberonics, Inc., for which we have worked since 1997.

Related Case Studies
	Syncardia Systems
	Organ Recovery Systems
	I-Flow Corporation
	Proxima Therapeutics
	SleepApneaInfo.com
	Hologic
	EnteroMedics
	Bioness, Inc.

Our Medical Device and Diagnostics Public Relations Clients

©2007 Schwartz Communications UK Limited, Inc.
Boston MA 781-684-0770 : San Francisco CA 415-512-0770 : Stockholm, Sweden +46 (0)8 586 107 61 : London +44 (0) 7507 651 010